Trial Profile
Carriage of 3GCREB in patients at risk for relapsing infection: randomized controlled trial of intestinal decolonization with colistin plus rifaximin.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jul 2019
Price :
$35
*
At a glance
- Drugs Colistin (Primary) ; Rifaximin (Primary)
- Indications Enterobacteriaceae infections
- Focus Therapeutic Use
- Acronyms Eradicate
- 16 Mar 2017 Status changed from suspended to discontinued.
- 28 Dec 2016 Status changed from recruiting to suspended.
- 29 Oct 2015 New trial record